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Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely due to inefficient 
diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells (PSCs) and 
consequent development of dense stroma are prominent features accounting for this aggressive 
biology1,2. The reciprocal interplay between PSCs and pancreatic cancer cells (PCCs) not only 
enhances tumour progression and metastasis but also sustains their own activation, facilitating a 
vicious cycle to exacerbate tumourigenesis and drug resistance3–7. Moreover, PSC activation 
occurs very early during PDAC tumourigenesis8–10, and activated PSCs comprise a significant 
fraction of the tumour mass, providing a rich source of readily detectable factors. Therefore, we 
hypothesized that the communication between PSCs and PCCs could be an Achilles’ heel 
exploitable to develop effective strategies for PDAC therapy and diagnosis. Here, starting with 
systematic proteomic investigation of secreted disease mediators and underlying molecular 
mechanisms, we reveal that leukemia inhibitory factor (LIF) is a key paracrine factor from 
activated PSCs acting on cancer cells. Both pharmacologic LIF blockade and genetic Lifr deletion 
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significantly slow tumour progression and augment chemotherapy efficacy to prolong survival of 
PDAC mouse models, mainly by modulating cancer cell differentiation and EMT status. 
Moreover, we show that, consistently in both mouse models and human PDAC, aberrant 
production of LIF in the pancreas is unique to pathological conditions and correlates with PDAC 
pathogenesis, and circulating LIF level changes correlate well with tumour response to therapy. 
Collectively, these findings uncover a previously unappreciated function of LIF in PDAC 
tumourigenesis, and suggest its translational potential as an attractive therapeutic target and 
circulating marker. These studies underscore how a better understanding of cell-cell 
communications within the tumour microenvironment promotes novel strategies for cancer 
therapy.
To comprehensively characterize the paracrine communication between PCCs and PSCs, we 
carried out integrated mass spectrometry (MS)-based quantitative proteomic analyses 
combining secretome profiling with phosphoproteomics (Fig. 1a). Phosphotyrosine 
proteomic analysis, performed to explore intracellular signaling events, revealed STAT3 
activation as a prominent event in PCCs in response to PSC conditioned medium (CM) 
stimulation, and in parallel secretomes of each cell type, MIAPaCa2 and hPSCs11 as 
representative lines, were individually profiled to quantitatively catalog the complete protein 
composition in the CM (Fig. 1b,c and Extended Data Fig. 1a–d). We then conducted IP-MS 
assays to explore STAT3-associated proteins, especially receptor(s), and found the LIF 
receptor (LIFR) and its co-receptor IL6ST/GP130 as the only receptors pulled down by 
STAT3 in a strictly CM stimulation-dependent manner (Fig. 1d,e and Extended Data Fig. 
1e). Consistently, LIF was produced by hPSC in copious amounts, but not by MIAPaCa2, 
pinpointing LIF as the key paracrine factor for STAT3 activation in PCCs (Fig. 1c).
LIF is a pleiotropic cytokine regulating cell differentiation, proliferation and survival in the 
embryo and the adult12, and is also involved in cancer development13–16. LIF production by 
PSCs was reported recently17–19, but its physiological significance in PDAC tumourigenesis 
is unclear. We firstly assessed LIF actions in vitro and found widespread response in PCCs 
but not in activated PSCs and normal fibroblasts, and among three reported downstream 
pathways12, mainly STAT3, but not ERK and AKT, was robustly activated (Extended Data 
Fig. 2a,b). Intriguingly, LIF signaling blockade by either LIFR knockdown in PCCs or LIF 
ligand immunodepletion from PSC CM effectively abolished STAT3 activation, 
corroborating LIF as the predominant paracrine factor for PCCs’ STAT3 activation (Fig. 1f,g 
and Extended Data Fig. 2c,d). Moreover, the variable response of PCCs to LIF was 
determined by LIFR level, and paracrine interaction was the predominant means of LIF 
action (Extended Fig. 2e,f). We then validated LIF dysregulation in vivo, and observed that 
LIF protein level was undetectable in normal pancreas but dramatically elevated in PDAC 
tissues (Fig. 1h). Furthermore, in both mouse and human PDAC tissues LIF mRNA was 
abundant in activated PSCs, especially in those adjacent to cancer cell nests, but sporadic in 
a small fraction of cancer cells, and barely detectable in CD45+ immune cells or normal 
pancreatic tissues, reaffirming activated PSCs as the major LIF-producing cells (Fig. 1i,j and 
Extended Data Fig. 2g). Correspondingly, STAT3 was also dramatically activated in PDAC 
tissues (Extended Data Fig. 2h–j). Together, these findings implicate the LIF involvement in 
PDAC pathogenesis.
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Although STAT3 activation has been documented to be essential for PDAC tumourigenesis, 
the underlying mechanisms and the cellular source(s) of STAT3-activating cytokines have 
been debated8–10,20. Based on our finding that PSC-produced LIF is a key STAT3 activator 
we evaluated its physiological significance in PDAC. Since PCCs are the major Lifr-
expressing cells and therefore presumably the main target of LIF action, we generated 
Lifrf/f;KPf/fCL compound mutant mice to assess the importance of PCC-intrinsic LIFR 
signaling for PDAC development physiologically (Extended Data Fig. 3a–d,k). The overall 
survival of Lifrf/f;KPf/fCL mice was significantly increased, indicating that LIFR signaling 
in PCCs per se plays an important role in PDAC development, and was further prolonged by 
gemcitabine (Gem) administration, implying an additional role in increasing 
chemoresistance (Fig. 2a). Correspondingly, the relative abundance of PCCs in tumours was 
significantly decreased in Lifr-deficient mice and by Gem treatment (Fig. 2b). Notably, 
although almost all pancreatic epithelial cells were transformed into cancer cells in 
LifrWT;KPf/fCL mice, distinct regions of pancreatitis and PanINs were still found in the 
pancreas of Lifrf/f;KPf/fCL mice at the study endpoint (Extended Data Fig. 3e). By 
comparing histopathological status of pancreatic tissues at various ages, corresponding to 
distinct stages of tumourigenesis, we found that, although at three weeks of age comparable 
amounts of PanINs and activated PSCs had evolved, by five weeks tumour progression in 
Lifrf/f;KPf/fCL mice was retarded with many fewer PCCs and activated PSCs, substantiated 
by dramatically lower tissue levels of PCC-produced Gm-csf21,22 and PSC-produced Ccl11 
(Fig. 2c–e and Extended Data Fig. 3f,g, 4j–o). Furthermore, when we accelerated PanINs 
initiation with caerulein in LifrWT;KC and Lifrf/f;KC mice to directly evaluate LIF effect on 
tumour initiation, comparable PanIN grades were induced (Extended Data Fig. 3h,i). 
Moreover, no apparent differences were observed in the formation and resolution of acinar-
ductal metaplasia between caerulein-treated LifrWT;Pdx1-Cre and Lifrf/f;Pdx1-Cre mice 
(Extended Data Fig. 3j). Altogether, these genetic studies demonstrated that LIF mainly acts 
on PCCs to facilitate tumour progression but not initiation.
Having established LIF as a promising therapeutic target, we evaluated it preclinically using 
the KPf/fCL mouse model with an anti-LIF neutralizing monoclonal antibody (mAb)23 
(Extended Data Fig. 5a–e). Reminiscent of genetic Lifr depletion, the overall survival of 
KPf/fCL mice was increased by anti-LIF mAb treatment, and further prolonged by Gem
+anti-LIF mAb (Combo) treatment with reduced tumour burden, even compared to Gem
+control IgG (Chemo), further corroborating the important roles of LIF in PDAC 
progression and chemoresistance (Fig. 3a,b). The Combo treatment significantly reduced 
PCC, but not PSC, abundance, and evaluation of PCCs showed increased proliferation 
accompanied by enhanced apoptosis (Extended Data Fig. 5f–j). An increase in PCC 
proliferation could enhance their susceptibility to Gem treatment, thus promoting apoptosis, 
and consequently alleviating chemoresistance. Blinded histopathological examinations by 
independent pathologists produced consistent interpretations that Combo-treated KPf/fCL 
tumours appeared more differentiated (Fig. 3c and Extended Data Fig. 6a), suggesting that 
LIF blockade promotes cancer cell differentiation and leads to a less aggressive and more 
drug-susceptible phenotype. To understand this effect, we assessed the relative abundance of 
PCCs by differentiation status and found that the populations of tumour-initiating cells 
expressing markers ALDH, CD133, CD24 and CD44, or cMet24–28, were all markedly 
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reduced by the Combo treatment, as functionally validated by both in vitro sphere formation 
and in vivo flank transplantation assays (Fig. 3d–f and Extended Data Fig. 6b–d), and 
consistently observed in the Lifr-deficient genetic model (Extended Data Fig. 4a–c). 
Furthermore, in short-term in vivo Combo-treated PCCs, besides tumour-initiating cell 
marker genes and those involved in negative regulation of stem cell differentiation, the 
expression of genes critical for epithelial-mesenchymal transition (EMT) were also 
downregulated, as further confirmed by reduced abundance of Zeb1+ mesenchymal PCCs 
(Fig. 3g and Extended Data Fig. 7b,c, 6e). Molecularly, the expression of many cascade 
components and downstream target genes in the Hippo, Wnt and STAT3 signalling pathways 
was significantly suppressed, together with expression changes leading to a heightened Gem 
response (Fig. 3h and Extended Data Fig. 7d,e). EMT induction and tumour-initiating cell 
emergence are intertwined biological processes facilitating chemoresistance in cancers and 
are regulated by several developmental signalling cascades including STAT3, Hippo and 
Wnt29. Moreover, the differential gene expression signatures were also recapitulated in the 
Lifr-deficient genetic model (Extended Data Fig. 4d–i and 7f,g).
We observed dual roles of LIF affecting both tumour progression and Gem response. Since 
delayed progression could impact Gem response, we assessed LIF’s direct effect on Gem 
sensitivity. When freshly isolated primary PCCs were subjected to low-dosage Gem, the 
sphere-forming capacity was markedly suppressed in Lifr-deficient PCCs, indicating that the 
intrinsic chemoresistance of tumour-initiating cells relied on LIFR signalling (Extended 
Data Fig. 6f). To validate this in vivo, we developed a maintenance PDAC mouse model by 
pretreating KPf/fC mice with nab-paclitaxel, cisplatin, and Gem combination30, and the 
Combo treatment caused an even more dramatic therapeutic benefit with substantially 
prolonged survival, characterized by markedly reduced mesenchymal-transited PCCs and 
increased PCC differentiation and apoptosis (Fig. 4a–e and Extended Data Fig. 6g–i). This 
evidence further emphasizes the importance of LIF in chemoresistance and reinforces its 
translational potential as a therapeutic target, given that PDAC is usually diagnosed late with 
strong intrinsic chemoresistance and therapeutics alleviating chemoresistance after the first-
line chemotherapy are urgently needed.
Since LIF mediates tumour progression, and LIF-producing PSCs are activated very early 
and gradually increase in abundance during PDAC tumourigenesis, we tested for correlation 
between LIF and PDAC pathogenesis. LIF levels were already markedly elevated in the 
pancreas of KPf/fCL mice at 3 weeks of age, when mainly pancreatitis and early PanIN 
lesions with a few small solid tumour nodules were evident, and then steadily increased 
during tumour progression (Extended Data Fig. 8a,3f). Notably, LIF elevation, along with 
STAT3 activation, was readily detectable in caerulein-induced pancreatitis, in which PSCs 
are transiently activated but tumour development is not yet initiated, substantiating LIF 
production by activated PSCs (Extended Data Fig. 2j, 8a–c). To examine its relevance to 
human PDAC, we quantified LIF levels in human pancreatic tissues, and observed a 
dramatic elevation in all 77 PDAC cases, compared to paired normal tissues, and an apparent 
trend of increase in chronic pancreatitis tissues (Fig. 5a and Extended Data Fig. 8e). Similar 
observations were recapitulated in an independent set of human pancreatic specimens by 
parallel reaction monitoring-based targeted mass spectrometry (PRM-MS) assays, which 
obviates potential limitations of ELISA assays (Extended Data Fig. 9a–e). More strikingly, 
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among various pathological parameters, LIF levels significantly correlated with PDAC 
differentiation status as well as overall survival, paralleling LIF mRNA levels revealed by 
TCGA RNA-seq data (Fig. 5b,c and Extended Data Fig. 8f,g). These correlations, albeit 
indirect, demonstrated LIF’s physiological importance in human PDAC pathogenesis, and 
added further evidence corroborating LIF regulation of cancer cell differentiation.
The correlation between LIF and tumour pathology in both mouse and human PDAC 
suggested LIF as a potential disease monitoring marker. Since clinical application requires 
easy and noninvasive sample acquisition, we evaluated LIF levels in blood samples by ultra-
sensitive ELISA assays and readily observed elevation in PDAC conditions (Fig. 5d and 
Extended Data Fig. 8d,i). Excitingly, among a cohort of 14 PDAC patients treated with 
preoperative chemotherapy with serial blood samples collected longitudinally during 
treatment, changes in circulating LIF levels significantly correlated with therapeutic 
responses, and were an independent and better indicator than Carbohydrate Antigen 19–9 
(CA19–9), the only FDA-approved PDAC biomarker in clinical use (Fig. 5e,f and Extended 
Data Fig. 8h). With regard to specificity, another critical requirement for a biomarker, LIF 
elevation, in both blood and primary tissues, was unique to PDAC compared to other 
common solid cancers (Extended Data Fig. 8i and 9f). Collectively, these findings 
highlighted LIF as a promising marker for monitoring PDAC status and/or therapeutic 
response.
IL6 has been implicated in PDAC, and all its family members, like LIF, bind to receptor 
complexes containing GP130 to activate similar signal cascades, such as the STAT3 
pathway. In our initial screens, IL6 and IL11 were also found to be produced by PSCs 
(Extended Data Fig. 10a–e). Since IL11 level was below its effective concentration (data not 
shown), we focused on side-by-side comparison of IL6 and LIF in PDAC. Surprisingly, 
while significantly elevated in mouse PDAC, IL6 was very low in both human PDAC 
primary tissues and blood (Extended Data Fig. 10f–i), below the detection threshold by 
PRM-MS (data not shown). Consistently, IL6 expression in human PDAC tissues was much 
lower and did not correlate with pathological parameters (Extended Data Fig. 10j–m,o). 
Moreover, consistent with our findings that fewer PCC lines responded to IL6, IL6R 
expression in human PDAC tissues was significantly lower, precluding IL6’s direct action on 
PCCs (Extended Data Fig. 10n–p). These findings underscore the importance of LIF over 
IL6 in human PDAC. Moreover, contributions of other PSC-secreted cytokines are likely 
minimal, since increased pSTAT3 was undetectable once both LIF and IL6 activity in hPSC 
CM were neutralized (Extended Data Fig. 10q).
In sum, using quantitative proteomics, we systemically investigated paracrine 
communication between PSCs and PCCs, and identified LIF as a critical stromal factor 
acting on PCCs. Functional studies revealed LIF’s physiological significance in driving both 
tumour progression and chemoresistance (Extended Data Fig. 8j), and highlighted its 
translational potential (details in Supplementary Discussion). This translational promise is 
reinforced and broadened by the significant correlation of tissue and circulating LIF with 
pathological parameters and its specific elevation and high abundance in PDAC. As such, 
LIF represents an attractive therapeutic target and biomarker in PDAC and warrants further 
comprehensive evaluation for its clinical application.
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Methods:
Cell lines.
The human pancreatic cancer cell lines AsPC1 (CRL-1682), BxPC3 (CRL-1687), CFPAC1 
(CRL-1918), MIAPaCa2 (CRL-1420), PANC1 (CRL-1469), and BJ fibroblasts (CRL-2522) 
were acquired from ATCC, KP4 (JCRB0182) from JCRB, and cultured per supplier’s 
instructions. HPDE6C7 was provided by Tsao group (U. Toronto) and cultured as previously 
described31. The spontaneously immortalized human pancreatic stellate cell line hPSC, 
ONO, and YAM1 were kindly provided by the Evans group (Salk) as previously described11. 
Normal human fibroblast cells were a kind gift from the Gage group (Salk). MEF cells for 
Lifr gene knockout characterization were isolated from individual embryos at E13.5, and 
cultured in DMEM containing 10% FBS for less than five passages. For the low dosage Gem 
treatment assay, 3 nM gemcitabine or vehicle (PBS) were used.
Mice.
KrasLSL-G12D/+;Trp53flox; Rosa26LSL-Luc compound mutant mice (denoted as KPf/fL mice) 
on FVB background were kindly provided by R. Shaw (Salk)32. Pdx1-Cre mice (stock # 
014647) were purchased from The Jackson Laboratory, and backcrossed with KPf/fL mice 
for at least 6 generations before phenotypic analysis. Frozen sperms of C57BL/6N-
Lifrtm1a(EUCOMM)Hmgu/H were purchased from the European Mouse Mutant Archive 
(EMMA) (order ID: 06941) and rederived by in vitro fertilization in the Salk Transgenic 
Core Facility to obtain the mutant mice (tm1a) harboring a knockout first allele (reporter-
tagged insertion with conditional potential), and then crossed with FLPo mice, 
Gt(ROSA)26Sortm2(FLP*)Sor/J, to delete the FRT-LacZ-Neo-FRT selection cassette and 
convert into Lifrflox (tm1c) strain with conditional allele. No phenotypic differences were 
noticed between Lifr+/+ and Lifrf/+ mice, and therefore data from Lifr+/+ and Lifrf/+ mice 
were combined and designated as LifrWT mice. No sexual dimorphism was noted in any 
mouse model, and therefore males and females were equally used for experimental purposes 
and both sexes are represented in all data sets. Mice were bred and maintained in the animal 
care facilities at the Salk Institute. Genotype of individual mice was determined by PCR 
using genomic DNA from tail biopsies with Bioline MyTaqTM Extract-PCR Kit. Standard 
PCR per manufacture protocol was performed, annealing at 58 or 60 °C for 35 cycles. 
Primer sequences are available upon requested. All animal experiments were performed 
according to protocols approved by the Salk Institute Animal Care and Use Committee.
Human specimens.
All the human frozen tissues and serum or plasma specimens were in existence, and 
provided as de-identified samples. Serial plasma samples were collected with the informed 
consent from the patients and provided to us for ELISA analysis with the approval by Salk 
Institutional Review Board (IRB) with protocol #17–0005. Human serum samples were 
provided by UCSD Moores Cancer Center BTTSR (supported by CCSG Grant 
P30CA23100), UNMC Rapid Autopsy Pancreatic Program (supported by P50CA127297, 
U01CA210240, P30CA36727, and 5R50CA211462), C.R. Becerra (supported by The 
Jeanne Shelby Fund for Cancer Research of Communities Foundation of Texas), and E. 
Borazanci.
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Lentiviral constructs and production.
shRNA constructs were purchased from The RNAi Consortium or Addgene as following: 
human shLIFR #1, TRCN0000430362 with target sequence 
ACTTCTGCAGATTCGATATTA, and #2, TRCN0000427511 with target sequence 
TGAAGTGTGTAACTAACAATT; scramble shRNA (shNC), Addgene # 1864 with hairpin 
sequence as 
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG. Lentivirus 
was produced in 293T cells transfected with shRNA constructs along with pRSV/REV, 
pMDLg/pRRE, and pCMV-VSVG packaging constructs. Viral supernatants were collected 
48 hr after transfection, spun for 5 min at 3,000 rpm, and filtered. Target cells were infected 
by incubation in viral supernatants for 6 hr, and selected with 2 mg/L puromycin 36 hr post 
infection.
Reverse transcription PCR and qPCR.
RNA was isolated using NucleoSpin RNA II kits (Clontech) and converted to cDNA using 
M-MLV Reverse Transcriptase (Invitrogen). Quantitative PCR was performed using ABI 
qPCR 7900HT (Thermo Fisher Scientific) by mixing cDNAs, Power SYBR Green PCR 
Master Mix (Invitrogen), and gene specific primers. ACTB were used as internal control for 
normalization. Data were analyzed by and analyzed by SDS2.4 software. Primer sequences 
are: hLIFR-qF: CGAGCCTATACAGATGGTGGA, hLIFR-qR: CCATTCTCGTTTCCGATA 
GC; hACTB-qF: TCCCTGGAGAAGAGCTACGA, hACTB-qR: 
TACAGGTCTTTGCGGATGTC.
RNA-seq and bioinformatic analysis.
Whole tumours from each mice were individually resected, dissociated into single cell 
suspension by enzyme digestion, and ~105 EpCAM+ pancreatic cancer cells were isolated 
by FACS and directly lysed in RA1 lysis buffer for RNA extraction using NucleoSpin RNA 
II kits (Clontech) per the manufacture’s protocol. All sequencing libraries were then 
sequenced at single-end 50 base-pair (bp) on Illumina HiSeq 2500 by the Salk Institute Next 
Generation Sequencing (NGS) Core. Raw sequencing data was demultiplexed and converted 
into FASTQ files using CASAVA (v1.8.2). Sequenced reads were quality tested using 
FASTQC33 (v0.11.2) with the default parameters. Alignment to the mm10 genome was 
performed using the STAR aligner34 (v2.4.0k). Mapping was carried out using default 
parameters (up to 10 mismatches per read, and up to 9 multi-mapping locations per read). 
Raw gene expression was quantified across all gene exons using the top-expressed isoform 
as proxy for gene expression, and differential gene expression analyses were carried out 
using the edgeR35 package (v3.6.8) using replicates to compute within-group dispersion. 
Differentially expressed genes were defined as having a false discovery rate (FDR) <0.05 
and a log2 fold change >0.8. Hierarchical clustering was performed using the R language 
(v3.3.2) with Ward’s hierarchical agglomerative clustering method and 1-cor as a distance 
metric. The heat map represents the differentially expressed genes that had a FPKM>2 in at 
least 4 samples, FDR <0.05 and a log2 fold change >0.8. Color represents expression from 
low (blue) to high (red). The gene set enrichment analyses (GSEA) were performed using 
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GSEA (v.2.2.0, Broad Institute)36. The STAT3 target gene list was referred to a previous 
report37.
RNA in situ hybridization by RNAscope or BaseScope.
RNA in situ hybridization for examining LIF, LIFR, IL6, IL6R, Ccl11 mRNA cellular 
localization was performed using RNAscope 2.5 HD Duplex, Multiplex Fluorescent V2 
Assay, or BaseScopeTM; Reagent Kit per the manufacturer’s instructions (Advanced Cell 
Diagnostics). Briefly, freshly resected tissues were immediately fixed in neutral buffered 
formalin for 26 hr at room temperature with continuous agitation, processed and embedded 
in paraffin. Five μm tissue sections were collected in RNase-free manner and dried at room 
temperature overnight. Staining was initiated by baking the slides for 60 min at 60 °C, and 
then deparaffinized. Pretreatment includes hydrogen peroxide for 10 min, antigen retrieval 
for 15 min, protease plus treatment for 15 min at 40 °C. Gene-specific target probe sets 
designed and supplied by the manufacturer were hybridized for 120 min at 40 °C, and 
sequential amplification steps were performed, and visualized in Red and/or Green, or in 
fluorescence.
Immunoblot.
Cell lysates were prepared with lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate with freshly added 1 mM Na3VO4, 1 μg/ml leupeptin and 1 mM PMSF. 
Protein lysates were resolved on SDS-PAGE gel and immunoblot quantification was carried 
out on an Odyssey Imager (Licor). α-Tubulin was used as loading control and blotted on the 
same membranes. The primary antibodies against the following proteins were used with 
indicated dilution: pSTAT3 (Cell Signaling, 9145, clone D3A7, lot 31, 1:1000), pAKT1 
(Cell Signaling, 4060, clone D9E, lot 23, 1:2000), and pERK1/2 (Cell Signaling, 4376, 
clone 20G11, lot 18, 1:1000), STAT3 (Santa Cruz, sc-8019, lot A1816, 1:500), LIFR (Santa 
Cruz, sc-659, lot 1714, 1:200), and ACTA2 (Santa Cruz, sc-32251, clone 1A4, lot A1218, 
1:5000), Krt19 (Epitomics, AC-0073, clone EP72, lot EL050102, 1:2000), α-Tubulin 
(Sigma, clone B-5-1-2, lot 086M4773v, T5186, 1:10,000).
ELISA.
Frozen tissue specimens were homogenized in cold Tissue Extraction Reagent II 
(Invitrogen) containing protease and phosphatase inhibitors (Complete mini and PhosSTOP, 
Roche) at 100 mg tissue per 1 mL and sonicated. 25 μL per well tissue lysate or serum 
without dilution were used for ELISA quantification. Mouse cytokine/chemokine Panel I kit 
(Millipore, MCYTOMAG-70K), and Human Circulating Cancer Biomarker Panel kit 
(Millipore, HCCBP1MAG-58K) customized by addition of the anti-LIF antibodies pair 
using our own anti-LIF mAb as capture antibody, were used for mouse and human samples 
respectively. The manufacture’s standard protocol was followed, and fluorescence intensity 
acquisition for each well and subsequent concentration calculation were carried out by Bio-
Plex 200 System (Bio-Rad). For the human serum or plasma specimens, Simoa-based ultra-
sensitive ELISA assays38, also customized with our anti-LIF mAb as capture antibody, were 
performed per Quanterix’s optimal protocol.
Shi et al. Page 9
Nature. Author manuscript; available in PMC 2019 October 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conditioned media (CM) preparation and proteomic secretome profiling.
Cells, seeded in high density a day before so as to reach around 95% confluence at use, were 
washed three times with PBS and then culture in serum free medium for 36 hr. CM were 
harvested and spun down for 5 min at 1000 g, filtered through a 0.22 μm filter. For CM 
stimulation assays on cultured cells, CM were used freshly or stored at 4°C for no more than 
3 days. For proteomic secretome profiling, the CM were concentrated by centrifuge through 
a 3K MW cut-off centrifugal filter (Millipore) at 4000 g for 30 min at 25°C, added PBS and 
spun two more times to exchange the buffer. The concentrated proteins were dissolved in 8 
M urea buffer containing 20 mM HEPES (pH 8), then reduced by dithiothreitol (Sigma), 
alkylated by iodoacetamide (Sigma), and digested by sequencing-grade trypsin (Promega). 
Digested peptides were de-salted using SepPak C18 cartridges (Waters) and fractionated into 
28 fractions by using strong-cation exchange (SCX) chromatography (PolySULFOETHYL 
Aspartamide, 2.1 mm × 200 mm, 5 μm, PolyLC) with 70 min gradient at flow rate of 0.3 
mL/min as reported previously39. Peptides in each fraction were then desalting by 
homemade C18 StageTip for MS analysis.
Phosphotyrosine proteomic analysis.
MIAPaCa2 or PANC1 cells at around 90% confluence were starved in serum free medium 
for 2 hr, and then stimulated with freshly prepared CM, or matched serum-free medium as 
control, for 5 min at 37 °C, washed with ice-cold PBS instantaneously and lysed with 8 M 
urea buffer containing 20 mM HEPES (pH 8) and 1 mM Na3VO4. The obtained proteins 
were reduced, alkylated and digested by TPCK-treated trypsin (Sigma). Digested peptides 
from two biological replicate samples with stimulation and one control sample were de-
salted using SepPak C18 cartridges in parallel and labeled using an on-column three-channel 
dimethyl labeling protocol40. The labeled peptides were then combined at 1:1:1 ratio and 
phosphotyrosine (pTyr) peptides were immunoenriched by two rounds of 
immunoprecipitation with 4G10-conjugated agarose beads (Millipore) as described 
previously41.
STAT3 IP-MS analysis.
The IP-MS experiments were performed as described previously41. Briefly, PANC1 cells 
stably expressing 3xFlag-tagged STAT3 were serum starved for 2 hr, and stimulated with 
freshly prepared hPSCs CM for 10 min at 37 °C, then immediately washed with ice-cold 
PBS and lysed in Nonidet P-40 lysis buffer containing protease and phosphatase inhibitors 
(Complete mini and PhosSTOP, Roche). The STAT3-associated proteins were 
immunoprecipitated with anti-Flag M2 beads (Sigma) and subjected to SDS-PAGE 
separation on NuPAGE 4–12% Bis-Tris Protein Gels (Thermo). To increase the sensitivity to 
identify membrane receptors usually at higher molecular weight, gel bands above 70 kDa 
were cut into 4 slices and subjected to in-gel digestion with sequencing-grade trypsin 
(Promega).
Mass spectrometry analysis and data processing.
1) For secretome profiling, the samples were analyzed on a TripleTOF 5600 mass 
spectrometer system (AB SCIEX) as described previously42. A 2.5 hr total LC gradient with 
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2% to 35% acetonitrile (ACN) over 120 mins was used. The obtained raw files were 
searched against IPI human database (v3.82, 92104 entries) using Mascot (v2.3.02) and 
processed for spectral counting quantification using Scaffold (v3.4.9). The edgeR35 package 
(v3.6.8) was used for generating the MA plot. Gene Ontology annotation was performed 
using DAVID (v6.8). 2) For phosphoproteomic and IP-MS analyses, the samples were 
analyzed on an LTQ-Orbitrap Elite mass spectrometer system (Thermo) as described 
previously41. A 3 hr total LC gradient with 5% to 35% ACN over 120 mins was used. The 
obtained raw files for phosphoproteomic analysis were processed by MaxQuant (v1.1.1.36) 
for dimethyl labeling quantification and database searching against IPI human database 
(v3.79, 91464 entries) with phosphorylation set as variable modification. Minimum ratio 
counts of 2 is required. IP-MS data was processed by MaxQuant (v1.2.2.5) for label-free 
quantification with “match between run” function activated and database searching against 
the IPI human database (v3.79). Only proteins quantified in all three biological replicates 
with peptide > 3 and “Razor + unique peptides” >1 were considered. 3) For global profiling 
of pancreatic tumour samples (Extended data Fig. 9b), the samples were analyzed on an 
Orbitrap Fusion mass spectrometer system (Thermo) as described previously43. A 4 hr total 
LC gradient with 3 to 7% ACN for 2 min, 7 to 22% ACN for 190 min, and 22 to 35% ACN 
for 30 min was used. The raw data were searched against the Uniprot human database 
(70611 entries, downloaded on July 23, 2016) by using Sequest HT node integrated within 
the Proteome Discoverer software (v1.4, Thermo). All the above-mentioned database 
searching was done with the standard settings expected for the specific annotations.
Tissue sample processing with glycoprotein enrichment for PRM-MS assays.
Frozen tissue specimens were homogenized in cold lysis buffer containing 100 mM sodium 
acetate, 150 mM NaCl, 2% SDS, 1% Triton-X 100, pH 5.5, and protease inhibitors 
(Complete mini, Roche) and sonicated. Glycosylated proteins, presumably mainly secreted 
ligands and transmembrane receptors, were selectively enriched using an improved 
hydrazide chemistry approach44. Briefly, the glycans in glycoproteins were oxidized by 2 
mM sodium periodate (Sigma) for 1 hr at 4 °C. Then 2 mM biotin-hydrazide (Sigma) was 
added to react with the aldehyde groups on oxidized glycans. Excess biotin-hydrazide and 
SDS were removed by protein precipitation. The protein pellet was redissolved in 8 M urea 
buffer containing 100 mM Tris-HCl, pH 7.8, reduced with DTT and alkylated with IAA as 
described above. After diluting the urea concentration to 2 M with a solution containing 100 
mM Na2HPO4, 150 mM NaCl, pH 7.5, glycoproteins conjugated with biotin-hydrazide were 
enriched by streptavidin beads (GE Healthcare) and digested with sequencing-grade trypsin 
(Promega). Peptide samples were fractionated by in-tip high pH fractionation into five 
fractions for global profiling or direct desalted by homemade C18 StageTip for PRM-MS 
assay.
PRM-MS quantification and data analysis.
PRM-MS assay was performed on the same Orbitrap Fusion system with the same LC 
setting as global profiling of tumour samples. 31 peptides (5 for LIF, 15 for LIFR, 11 for 
GP130) identified from various biological samples, as summarized in Extended Data Table 
2, were programmed for the PRM assay with these criteria applied: unique peptide, no 
dynamic modification, no more than one missed cleavages, appropriate sequence length and 
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clear mass fragment spectrum. The PRM acquisition method was developed as referred to a 
previous study45 by combining a full MS scan followed by up to 32 PRM scans of precursor 
ions within the scheduled retention time window (± 25 min of the average retention time 
detected in the profiling assay). The full MS scans were collected from m/z 350 to 1200 at 
resolution of 60,000 (at m/z 200), AGC target of 2×105 and maximum injection time of 100 
ms. Target precursors were then isolated through a window of 2 Th, followed by 
fragmentation at normalized collision energy of 30%. The product ions were scanned with 
resolution of 30,000 (at m/z 200), AGC target of 2×105, and maximum injection time of 120 
ms. The PRM raw data were firstly searched against the Uniprot human database by using 
Sequest HT. The most frequently identified peptides across all the samples were chosen for 
quantitation. All raw data were analyzed by Skyline (v3.6.0.10493)46 to extract and calculate 
the transition peak areas and manually inspected by single experienced person. Data met the 
following four criteria, normalized retention time (iRT) within ± 2 min, linear regression > 
0.98, mass difference within ± 20 ppm and dot-product (dotp) score ≥ 0.75, were accepted 
for further analysis. Relative abundance was calculated by normalizing against the highest 
intensity in the panel.
Animal studies.
Mouse tumour wet weight was measured immediately following resection, or tumour 
volume (Fig. 3f) was calculated using the standard modified ellipsoid formula 1/2 (length × 
width2). For all survival studies, the moribund state or maximal tumor size (20 mm in 
diameter) allowed by our IACUC was used as the clinical endpoint. For caerulein treatment, 
mice at 7 weeks of age were subjected to 250 mg/kg body weight caerulein (Bachem) 
treatment by IP injection with various frequencies: LifrWT- or Lifrf/f- KrasLSL-G12D/+;Pdx1-
Cre mice were treated daily for 5 days and rested for 5 days to evaluate tumour initiation; 
LifrWT;Pdx1-Cre or Lifrf/f;Pdx1-Cre mice were treated daily for 7 days and pancreas tissues 
were collected 1 or 7 days after the last injection to examine ADM formation and resolution; 
wildtype CD1 mice (Jax Lab, 003814) were treated twice daily for 5 days per week for 2~4 
weeks to induce chronic pancreatitis development. For the short term treatment for RNA-seq 
analysis (Fig. 3g,h), 6-week KPf/fCL mice were treated with 50 mg/kg Gem twice (on day 1 
and 4) plus either 25 mg/kg control IgG or anti-LIF mAb thrice (on day 1, 3, 5) in five days, 
and tumours were resected on day 6. For the maintenance PDAC model (Fig. 4a), 5-week 
KPf/fC mice were administered with 50 mg/kg nab-paclitaxel by IV from tail vein followed 
with 80 mg/kg gemcitabine and 4 mg/kg cisplatin by IP every four days for three times, then 
after three days off, 50 mg/kg gemcitabine twice weekly together with 25 mg/kg control IgG 
or anti-LIF mAb thrice weekly were administered by IP till study endpoint. Sample size 
were not pre-determined by statistical evaluation.
Flow cytometry, tumour sphere formation and in vivo transplantation assays.
Mouse pancreatic tumour dissociation and subsequent flow cytometry analysis or cell 
sorting for pancreatic tumour sphere formation and in vivo transplantation assays were 
carried out on a FACSAria III machine and data analysis by FlowJo software (Tree Star) as 
previously described28.
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Histology and immunostaining.
Mouse tumours were resected, fixed in 10% neutral buffered formalin overnight at 4 °C, and 
paraffin embedded according to standard protocol. 5 μm sections were processed for 
Haematoxylin and Eosin (H&E), Masson’s Trichrome, or Alcian Blue-Periodic Acid Schiff 
(AB-PAS) stainings per standard protocol. For immunohistochemistry (IHC) staining, tissue 
sections were first deparaffinized in xylene and rehydrated in graded ethanols. Antigen 
retrieval was performed for 15 min in 95–100 °C 10 mM sodium citrate buffer, pH 6.0, or 
1mM EDTA, pH 8.0 (for pSTAT3 antibody). Then, endogenous peroxidase activity was 
quenched by 3% H2O2 for 10 min. Sections were blocked in TBS containing 0.1% Triton 
X100 (Sigma) and 5% goat or donkey serum (Vector Laboratories). Incubations with 
primary antibodies were performed overnight at 4 °C in a humidified chamber, followed 
with appropriate SignalStain Boost IHC Detection Reagent (Cell Signaling Technology) for 
30 min, or with biotinylated secondary antibodies for 45 min and then ABC Elite for 30 min 
(Vector Laboratories), all at room temperature. ImmPACT DAB Kit (Vector Laboratories) 
was used to develop signals per manufacturer’s instructions. Sections were counterstained 
with Haematoxylin (Sigma). Multiplex immunofluorescence staining was carried out 
similarly to IHC staining, except that sections were blocked in PBS containing 0.1% Triton 
X100, 10% donkey serum, and 5% bovine serum albumin (Millipore), and incubation with 
Alexa Fluor-conjugated secondary antibodies (Molecular Probes) was performed for 1 hr at 
room temperature. 4′,6-Diamidino-2-phenylindole (DAPI) (Molecular Probes) was used to 
stain genomic DNA. The following primary antibodies were used with indicated dilution: 
mouse anti-ACTA2 (Santa Cruz sc-32251, 1:1500), rabbit anti-Cytokeratin 19 (Epitomics 
AC-0073, 1:200), rabbit anti-phospho-Stat3 (Tyr705) (CST 9145, 1:100), rabbit anti-cleaved 
Caspase 3 (CST 9661, lot 37, 1:200), rabbit anti-Ki67 (Abcam ab15580, lot GR264768–1, 
1:3000), rabbit anti-Zeb1 (Abcam ab87280, lot GR3186880–1, 1:500), and goat anti-Pdx1 
(Abcam ab47383, lot GR295217–1, 1:5000).
Images acquisition and quantification analysis.
Histology and IHC images were acquired with a Pannoramic MIDI slide scanner 
(3DHISTECH). Automated batch quantification of IHC images was performed with custom 
ImageJ47 macros enabling the Bio-formats plugin48. In brief, color images were converted 
into 8-bit grayscale images and then a two-threshold strategy was applied to quantify the 
percentage of positively stained area over total tissue area, denoted as relative ratio, for each 
tissue sample. Total tissue area was measured using a low threshold value (threshold = 9, 
above the background in the blank area), and αSMA+ or Krt19+ regions were similarly 
quantified using appropriately high threshold values (threshold = 145 and 150, respectively). 
Fixed threshold values were applied for analysis of all images.
Since both PCCs and PSCs in a certain fraction are proliferating (Ki67+) or mesenchymal 
(Zeb1+), to quantitatively assess the ratio of proliferating or mesenchymal over the total 
population of PCCs (Pdx1+)49 specifically, we employed the multiplex immunofluorescence 
co-staining strategy to mark proliferating or mesenchymal cells and tumour cells 
independently and simultaneously define the proliferating or mesenchymal tumour cells as 
those with double positive signals. Multiplex immunofluorescence tissue section images 
were acquired using the VS120-L100 Virtual Slide System (Olympus) at 20x objective 
Shi et al. Page 13
Nature. Author manuscript; available in PMC 2019 October 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
magnification with a consistent scanning setting across the same set of experiments. Prior to 
quantification, background subtraction using a 512 μm Gaussian filter was applied. Positive-
stained nuclear signals were defined by automated surface detection function using Imaris 
software (Bitplane). Any two surfaces with overlapping area larger than a fixed threshold 
(27.56 μm2 for red/blue and 78.74 μm2 for magenta/blue) were counted as double positive 
surfaces. The number of blue (DAPI+) surfaces corresponded to the total number of cells, 
and the number of magenta (Pdx1+) and blue (DAPI+) double positive surfaces indicated the 
total number of cancer cells, and the number of red (Ki67+ or Zeb1+)/magenta (Pdx1+)/blue 
(DAPI+) triple positive surfaces indicated the number of proliferating cancer cells. Statistics 
were calculated using a custom MATLAB extension code of Imaris software. One tissue 
section (the entire tissue region of the section) per animal was analyzed, quantified as a 
whole, and represented as a single data point for all the assays.
Statistical analysis.
Statistical analyses were performed using Prism (v8.0a, GraphPad Software). Sample sizes 
were determined on the basis of the variability of pancreatic tumour models used. Tumour-
bearing animals were randomly assigned to the treatment groups. Two-tailed unpaired 
Student’s t-test or Mann-Whitney test for two-group comparison, one-way ANOVA with 
Tukey’s multiple comparisons test or Kruskal Wallis for multiple-group comparison, and 
Mantel-Cox Log-rank test for survival comparison, were used where appropriate to 
determine statistical significance. Tumour tissue LIF levels were correlated to survival time 
by nonparametric Spearman correlation test. Coupling the receiver operating characteristic 
curve (ROC) with its area under the curve (AUC), a widely used method to estimate the 
diagnostic potential of a classifier in clinical applications, was performed using the pROC 
package for R50. Circulating LIF and CA19–9 concentrations were normalized to initial time 
point for each patient to circumvent variations among patients. The disease response codes 
(0 = partial/good response; 1 = progression, scored by RECIST standard in clinics) were 
used as the standard to instruct the actual trend of change. For all the statistical analyses, *, 
P<0.05; **, p<0.01; ***, p<0.001, and data are shown as the mean ± SEM.
Data availability.
All source data for full IB scan images and statistical analysis presented in Figure panels 
were included in the Supplementary materials. RNA sequencing data have been deposited in 
the Gene Expression Omnibus under accession numbers GSE99187 and GSE119694. All 
MS raw data have been deposited to the MassIVE repository (ftp://massive.ucsd.edu/
MSV000081136). The custom scripts for quantification of IHC images with Image J and 
multiplex immunofluorescence images with Imaris will be freely available upon reasonable 
request.
Extended Data
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Extended Data Figure 1 |. Combinatorial MS analyses to characterize the paracrine 
communication between PSCs and PCCs.
a, Phosphotyrosine proteomic analysis of intracellular signaling changes in MIAPaCa2 cells 
in response to hPSC CM stimulation. n=2 biological replicates. b. Summary of 
phosphotyrosine proteomic analysis data in PANC1 and MIAPaCa2 in response to hPSC 
CM stimulation. c, Workflow of the analysis of secretome proteomic assays. Proteins 
identified with at least three spectral counts were counted, and only those identified in both 
biological replicates were considered. Proteins uniquely secreted by each cell type were 
defined as those with more than 10-fold differences in spectral count. n=2 biological 
replicates. d, DAVID gene ontology (GO) analysis of the protein sets uniquely secreted by 
MiaPaCa2 and hPSC respectively identified the top ten enriched GO terms of molecular 
function for each cell type. e, Pearson correlation analysis to validate the quantification 
reproducibility of STAT3 IP-MS assays by label-free quantification (LFQ) between 
biological replicates. n=3 biological replicates for both control and PSC CM stimulation.
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Extended Data Figure 2 |. Dysregulated LIF is a key driver for STAT3 activation in PDAC.
a, IB analyses of the response of various human PCC and PSC cell lines to LIF stimulation, 
using STAT3 phosphorylation at Y705 (pSTAT3) as a readout. b, IB analyses of LIF-
stimulated downstream intracellular signaling changes in three representative PCC lines, 
KP4, MIAPaCa2 and PANC1, over a two-hr time course. 10 ng/mL recombinant human 
EGF stimulation for 10 min was used as positive control for pAKT1 and pERK1/2 
activation. c,d, IB analyses of pSTAT3 in MIAPaCa2 and PANC1 cells when LIF signaling 
was blocked by either shRNA knockdown of LIFR (c) or immune-inactivation of LIF using 
anti-LIF mAb (d). For LIF stimulation (a-d), 1 ng/mL recombinant human LIF was applied 
for 15 min, and at least three independent experiments were performed and representative 
images were presented. e, LIFR expression in PCCs by qPCR and its positive correlation 
with the response intensity to LIF as illustrated in the heatmap. n=2 biological replicates. f, 
LIF secretion by PCCs and PSCs quantified by ELISA, and its negative correlation with the 
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corresponding response intensity to LIF. n=2 biological replicates. g, Cellular localization of 
Lif mRNA in pancreatic tumour tissues from KPf/fCL mice was examined by multiplex 
fluorescent RNAscope assays. Ptprc/Cd45 mRNA was co-stained to mark immune cells, and 
Krt19 was stained by IF to mark cancer cells. Scale bars: red, 200 μm; white, 50 μm. h-j, 
pSTAT3 analyzed by IB (h) and immunohistochemistry (IHC) (i) in mouse pancreatic 
tissues, and by IHC in human pancreatic tissues during the pathogenesis of PDAC (j). NT, 
mouse normal tissues or non-tumour parts resected from the human tumour trunks; CP, 
chronic pancreatitis; PDAC, pancreatic tumour tissues collected from KPf/fCL mice or 
PDAC patients. Scale bars: black, 500 μm; blue, 100 μm. For the histology assays on tissue 
sections (g,i,j), at least three tumour samples were stained and analyzed, and representative 
images were presented.
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Extended Data Figure 3 |. Intrinsic LIFR signaling in PCCs affected pancreatic cancer 
progression but not initiation and ADM development.
a, Cellular localization of Lifr mRNA in mouse pancreatic tissues by RNAscope assays. 
Postn mRNA was co-stained to mark the stromal PSC cells. b, Schematic illustration of Lifr 
mutant allele structure and conversion into conditional deletion mutant allele by FLPo 
excision. c,d, Characterization of primary mouse embryonic fibroblasts isolated from Lifrf/f 
and LIFRf/+ mice respectively, by PCR analysis to determine the genotype of the Lifr allele 
and loxP-flanked exon deletion by Adenovirus-introduced Cre (c), and by IB analysis to 
validate the knockout of Lifr proteins and loss of response to LIF (d). +, wildtype allele; f, 
loxP-flanked mutant allele; ∆, mutant allele with the loxP-flanked exon deleted. e, 
Representative histological images characterizing the tumours from LifrWT- or Lifrf/f- 
KPf/fCL mice respectively at the endpoint of survival study presented in Fig. 2b. f,g, 
Histology characterization of tumour development in LifrWT- or Lifrf/f- KPf/fCL mice at 3, 
5, and 7 weeks of age (f), and quantification of cancer cell abundance (g); n=6 mice per 
condition. h,i, Pathological grade of tumour stage (h) and histological quantification of 
cancer and stromal PSC cell abundance (i) for pancreatic tissues collected from LifrWT- or 
Lifrf/f- KC mice treated with 250 mg/kg caerulein by daily IP injection, starting at 7 weeks 
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of age, for 5 days and rested for 5 days to allow tumour development. j, Histology 
characterization of caerulein-induced ADM development and resolution in LifrWT;Pdx1-Cre 
or Lifrf/f;Pdx1-Cre mice by Masson’s trichrome stain. Littermates at 7 weeks of age were 
subjected to daily 250 mg/kg body weight caerulein treatment by IP injection for 7 days, and 
pancreas tissues were collected 1 or 7 days after the last injection to examine the ADM 
formation and resolution. No differences were noticed between two genotypes. n=5 mice per 
condition. k, RNA in situ hybridization by BaseScope assays using probes specifically 
targeting the loxP-flanked exon 4 of Lifr to examine the escaper cancer cells still 
maintaining Lifr expression due to incomplete deletion. Scale bars: black, 1000μm; blue, 
200μm; yellow, 50μm. Statistical significance was determined by two-way ANOVA (h) or 
two-tailed unpaired Student’s t-test.
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Extended Data Figure 4 |. LIFR signaling in PCCs modulated cancer cell differentiation.
a,b, Flow cytometry analysis of the total cell counts (a) and relative frequency (b) of 
tumour-initiating cell populations in individual tumours. c, Functional evaluation of tumour-
initiating cell abundance by in vitro sphere formation. d-i, Differential gene expression 
comparing the EpCAM+ cancer cells purified from individual tumours of LifrWT- or Lifrf/f- 
KPf/fCL mice, are shown in heat maps. Colors correspond to standardized expression of 
genes. n=4 mice per treatment. d, Hierarchical clustering of all the 1129 differentially 
expressed genes (FDR < 0.05, log2 fold change > 0.8 and FPKM>2 in at least 4 samples). 
Heat maps of genes related to tumour-initiating cell markers (e), STAT3 downstream targets 
(f), and Gem response (g). h,i, Gene set enrichment analysis (GSEA). j,l, Csf2 (encoding 
Gm-csf) and Ccl11 genes expression in EpCAM+ PCCs, Pdgfrα+ CAFs and Ptprc/Cd45+ 
tumour infiltrating lymphocytes (TILs), purified by FACS from tumours of KPf/fCL mice, by 
RNA-seq analysis. n=4, 3, 3 respectively. k,m,n, Multiplex ELISA analysis of Gm-csf and 
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Ccl11 levels in normal, caerulein-induced chronic pancreatitis (CP), and PDAC tissues of 
KPf/fCL mice showed that the increase in Gm-csf was induced only when tumours 
developed (k), while the increase in Ccl1l level was induced in both CP and PDAC 
consistently both in mouse models (m) and human disease (n), supporting the notion that 
Ccl11 is a cytokine specifically produced by PSCs while Gm-csf specifically by PCCs. o, 
Cellular localization of Ccl11 mRNA in pancreatic cancer tissues from KPf/fCL mice was 
examined by multiplex fluorescent RNAscope assays. Ptprc/Cd45 mRNA was co-stained to 
mark immune cells, and Krt19 stained by IF to mark cancer cells. n=3 tumours. Scale bars: 
yellow, 500μm; white, 100μm.
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Extended Data Figure 5 |. Preclinical study in KPf/fCL mouse model revealed therapeutic 
beneficial effects of LIF blockade by anti-LIF mAb.
a-d. Anti-LIF mAb production and characterization. a, Silver staining of control mouse IgG 
and purified anti-LIF mAb used for preclinical treatment. b,c, IB analysis to evaluate the 
activity and specificity of anti-LIF mAb against various forms of LIF (rhLIF, recombinant 
human LIF; ehLIF, eukaryotically secreted human LIF; rmLIF, recombinant mouse LIF) and 
IL6 (b) and revealed that the anti-LIF mAb has weaker neutralizing activity against mLIF 
compared to hLIF (c). d, Pilot test of anti-LIF mAb in KPf/fCL mice for dosage 
optimization. KPf/fCL mice at 42 days of age were administered with 25 mg/kg body weight 
of anti-LIF mAb by IP injection every other day for three times, and one day after the last 
injection tumours were collected for histology analysis. Adjacent sections were used for the 
indicated staining. Representative images from three independent experiments or mice were 
showed. e, Regimen for the preclinical therapeutic treatment. KPf/fCL mice at 5 weeks of 
age were randomly enrolled into four cohorts. For the first 12 days as phase one, 25 mg/kg 
anti-LIF mAb or control IgG were administered by IP injection, together with 50 mg/kg 
Gem or vehicle at standard Q3D4 dosage. This was followed by weekly cycles as phase two 
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with antibodies thrice and Gem twice weekly. f, Histological characterization with 
representative images and cell abundance quantification. g, Relative abundance of EpCAM+ 
cancer cells quantified by flow cytometry analysis. h, Double immunofluorescence staining 
to confirm the cell type specific expression of cytosolic protein Krt19 and nuclear protein 
Pdx1 as the PCC marker. n=3 tumour tissues. i, Double immunofluorescence staining of 
nucleus-localized proteins Ki67 (used as a proliferation marker) and Pdx1 (as the PCC 
marker), and quantification of proliferating cancer cell frequency as the fraction of 
proliferating cancer cells (Ki67+/Pdx1+/DAPI+) over total cancer cells (Pdx1+/DAPI+). j, 
Cleaved Caspase 3 IHC analysis to assess apoptosis. Scale bar, yellow, 300 μm; black, 
100μm; white, 50 μm. Statistical significance was determined by two-tailed unpaired 
Student’s t-tests.
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Extended Data Figure 6 |. LIF blockade alleviated chemoresistance directly by affecting cancer 
cell differentiation.
a, Representative histological images showing different tumour differentiation status. b-d, 
Flow cytometry analysis of the total cell count (b) and relative frequency (c) of tumour-
initiating cell populations in individual tumours, and the gating strategy exemplified with 
representative contour plots (d). e, Multiplex immunofluorescence staining of nuclear 
proteins Zeb1 (as a mesenchymal cell marker) and Pdx1 (as the PCC marker) and 
quantification of mesenchymal cancer cell frequency as the fraction of Zeb1+/Pdx1+/DAPI+ 
cancer cells over Pdx1+/DAPI+ total cancer cells. f, Sphere formation assays on primary 
PCCs with or without Lifr deficiency in response to low concentration (3 nM) Gem 
treatment. n=9 per condition. g-i, Histological characterization of tumour tissues from the 
maintenance study (ref to Fig. 4c–e), and representative images of AB-PAS staining for 
well-differentiated cancer cells with acidic and neutral mucin stained in blue and magenta 
(g), of multiplex immunofluorescence staining of Zeb1 and Pdx1 proteins for the 
mesenchymal cancer cell frequency quantification and EMT (h), and of Cleaved Caspase 3 
IHC analysis for apoptosis (i). Scale bars: black, white, 300μm; blue, 100μm; yellow, 50μm. 
Statistical significance was determined by two-tailed unpaired Student’s t-test.
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Extended Data Figure 7 |. LIF blockade profoundly affected genes expression in cancer cells 
analyzed by RNA-seq.
a-e, Differential gene expression comparing the EpCAM+ cancer cells purified from 
individual tumours of KPf/fCL mice treated with either Gem+control IgG (GI) or Gem+anti-
LIF mAb (GA) are shown in heat maps. Colors correspond to standardized expression of 
genes. a, Hierarchical clustering of all the 1624 differentially expressed genes (FDR < 0.05, 
log2 fold change > 0.8 and FPKM>2 in at least 4 samples). b, Gene set enrichment analysis. 
Heat maps presenting the expression levels of genes related to tumour-initiating cell markers 
(c), STAT3 downstream targets (d), and Gem response (e). f, Venn diagram comparing the 
differentially expressed genes by pharmacologic LIF blockade and genetic Lifr deficiency 
revealed 811 consensus genes. g, Hierarchical clustering of 811 consensus genes with 
differential expression by either pharmacologic LIF blockade and genetic Lifr deficiency.
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Extended Data Figure 8 |. Correlation analysis between tissue LIF levels and clinical parameters 
of PDAC.
a-c, ELISA analysis of Lif levels (a), and IB and IHC analyses of STAT3 activation in 
mouse pancreatic tissues at various stages of PDAC pathogenesis. Scale bars: black, 200μm; 
blue, 50μm. d, Mouse serum Lif levels at various stages of pancreas pathogenesis analyzed 
by ELISA. e, Summary table of clinical parameters of the human cases from whom 
pancreatic tissue samples were collected for ELISA assays and correlation analysis. f, 
Correlation analysis of human tissue LIF levels and indicated clinical parameters by Chi 
square analysis. g, Correlation analysis between tissue LIF mRNA levels and disease free 
survival of patients with stage I or IIa PDAC at diagnosis by Mantel-Cox Log-rank test and 
presented as Kaplan-Meier survival curve. Data derived from TCGA database. h, 
Correlation analysis between the changes in circulating LIF or CA19–9 levels and tumour 
status scored by RECIST grade during multi-cycle therapeutic treatment by the receiver 
operating characteristic (ROC) analysis. n=51 data points. i, Serum LIF levels in various 
solid cancer patients by Simoa ELISA. j, Graphic summary of LIF action in pancreatic 
carcinogenesis.
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Extended Data Figure 9 |. PRM-MS assay development and analysis.
a, Schematic workflow of the glycoprotein enrichment strategy followed with PRM-MS 
assays. b, Identified unique peptides of the targeted proteins in human pancreatic tissues. c, 
Reproducibility evaluation of the tissue sample preparation and PRM-MS analysis. d, 
Summary table of clinical parameters of the human cases from whom pancreatic tissue 
samples were collected for PRM-MS analysis. e,f, LIF protein levels in human primary 
tumour and paired normal tissue samples from pancreatic cancer patients (e) and various 
solid cancer patients (f) quantified by PRM-MS assays. g,h, LIFR and GP130 protein levels 
in human pancreatic tissues quantified by PRM-MS assays. Statistical significance was 
determined by two-tailed unpaired Student’s t-test (f) or one-way ANOVA (e,g,h); *, 
p<0.05; ***, p<0.001.
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Extended Data Figure 10 |. Comparison of LIF and IL6 in PDAC.
a,b, MS and ELISA quantification of IL6 family cytokines in hPSC CM. n=2 biological 
replicates. c-e, ELISA quantification of IL6 (c) and IL11 (d) in CMs of various human PCC 
lines, and LIF and IL6 in CMs from various human PSC or normal fibroblast cells (e). n=2 
biological replicates. f-i, ELISA quantification of LIF and IL6 levels in mouse and human 
pancreatic tissues (f,g) and sera respectively (h,i). j,k, Correlation analysis between human 
tissue IL6 levels and tumour differentiation status by Kruskal-Wallis test (j) or overall 
survival by Pearson correlation test (k). l-n, Correlation analysis between tissue IL6 mRNA 
levels and overall survival by Mantel-Cox Log-rank test presented as Kaplan-Meier survival 
curve (l), and mRNA expression compared by Wilcoxon matched-pairs rank test and 
presented as Tukey box-and-whisker plots (m,n); RNA-seq data of 170 PDAC tissues were 
derived from TCGA database. o, Cellular localization of mRNA expression in human 
pancreatic tissues examined by RNAscope assays. KRT19 or POSTN were co-stained to 
mark PCC and PSC cells respectively. p,q, IB analysis of pSTAT3 activation in indicated 
human pancreatic cancer cell lines in response to 1 ng/mL recombinant human IL6 or LIF 
stimulation (p) or the stimulation by hPSC CM with or without immune-inactivation of LIF 
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and/or IL6 using neutralizing antibodies (q). 15 min stimulation were carried out for all. 
Representative images from three independent experiments were showed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1 |. Combinatorial MS analyses identified LIF as a key paracrine factor.
a, Schematic workflow of the MS strategy combining secretome and phosphoproteomic 
analyses. Matched serum-free medium was used as control stimulation. b, Phosphotyrosine 
proteomic analysis of CM-stimulated intracellular signalling in PANC1 cells. c, Proteomic 
analysis and comparison of MIAPaCa2 and hPSC secretome presented as an MA plot. n=2 
biological replicates (b,c). d,e, IP-MS assay on 3xFlag-STAT3-expressing PANC1 cells to 
identify CM stimulation-dependent STAT3-associated proteins. n=3 biological replicates. 
f,g, IB analyses of pSTAT3 in KP4 cells with LIF blockade by LIFR knockdown or anti-LIF 
mAb. CM harvested from hPSC. h, Lif levels in mouse pancreatic normal and tumour 
tissues by ELISA. NT=7; PDAC=8. i,j, RNAscope assays to examine cellular sources of LIF 
mRNA expression in mouse (i) and human (j) pancreatic tissues. Krt19 mRNA was co-
stained to mark cancer cells. NT, mouse normal pancreatic tissues or non-tumour parts 
resected from the human tumour trunks; PDAC, tumour tissues collected from KPf/fCL mice 
or PDAC patients. Scale bars: black, 200 μm; blue, 50 μm. Representative images from at 
least three biological replicates per experiment were presented (f,g,i,j).
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Figure 2 |. LIF acted on PCCs to affect tumour progression.
a, Kaplan–Meier survival curve. b, Relative abundance of Krt19+ cancer cell in tumours at 
the endpoint of the survival study. c-e, Pathological grade of tumour stage, histological 
quantification of cancer and stromal PSC cell abundance, and levels of PCC-produced Gm-
csf and PSC-produced Ccl11 by Luminex multiplex ELISA assays in tumour tissues 
collected from five-week LifrWT- or Lifrf/f- KPf/fCL mice. Statistical significance was 
determined by one-way ANOVA with Tukey’s multiple comparisons test (a,b), two-way 
ANOVA (c), or two-tailed unpaired Student’s t-test (d,e).
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Figure 3 |. LIF blockade by anti-LIF mAb provided therapeutic benefit in PDAC by affecting 
cancer cell differentiation.
a, Kaplan–Meier survival curve. b, Total tumour weights at the endpoint of treatment. c, 
Pathological grade of tumour differentiation. n=6 mice per treatment. d, Flow cytometry 
analysis of total count of tumour-initiating cells, defined as ALDH+ or EpCAM+/CD133+, in 
individual tumours. e,f, Functional evaluation of tumour-initiating cell abundance by in vitro 
sphere formation and in vivo flank transplantation assays. g,h, Gene set enrichment analysis 
(GSEA) for differential gene expression in EpCAM+ cancer cells freshly isolated by FACS 
from individual tumours of the in vivo Chemo or Combo treated KPf/fCL mice. n=4 mice 
per treatment. Statistical significance was determined by one-way ANOVA (a), or two-tailed 
unpaired Student’s t-test.
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Figure 4 |. LIF blockade directly affected chemoresistance in PDAC.
a, Regimen for the preclinical maintenance therapeutic trial. b, Kaplan–Meier survival 
curve. c-e, Histological quantification of cancer cell differentiation by AB-PAS staining (c), 
mesenchymal transition by Zeb1/Pdx1 immunofluorescence co-staining (d), and apoptosis 
by Cleaved Caspase 3 IHC (e). Statistical significance was determined by one-way ANOVA 
(b), or two-tailed unpaired Student’s t-test.
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Figure 5 |. LIF can be a biomarker for PDAC monitoring.
a-c. LIF levels in human pancreatic tissues quantified by ELISA (a), and their correlation 
with tumour differentiation status (b) and overall survival (c). n, NT=9; CP=5; PDAC=77. d, 
Human circulating LIF levels quantified by Simoa ELISA. n, NT=24; PDAC=69. e, 
Comparison of circulating LIF and CA19–9 levels in paired human PDAC plasma. Lines 
connect the paired samples from the same cases. n=28. f, Correlation of circulating LIF level 
changes and therapeutic responses in PDAC patients. Lines connect the paired samples per 
patients. n=14. Statistical significance was determined by Kruskal-Wallis test (a,b), 
nonparametric Spearman correlation test (c,e), Mann Whitney test (d), or Fisher’s Exact Test 
(f).
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